美国普通人群痛风患者过早死亡差距未缩小,且不依赖于血清尿酸和动脉粥样硬化性心血管危险因素
基于美国全国性前瞻队列,校正血清尿酸、动脉粥样硬化性心血管危险因素、合并症、用药及肾功能后,痛风患者全因死亡风险在早期(1988-1994)和晚期(2007-2016)队列中相似(HR分别为1.20和1.19),英国晚期队列为1.61;心血管死亡风险亦升高。结论认为痛风患者存在持续性死亡差距,支持痛风特异性通路的作用。
要点
- 美国早期和晚期队列中痛风患者全因死亡校正HR分别为1.20和1.19,进一步校正血清尿酸后均为1.19。
- 英国晚期队列痛风患者全因死亡校正HR为1.61,女性中关联更大(P=0.04),黑人个体中突出。
- 美国晚期队列心血管死亡校正HR为1.39;英国痛风患者循环系统、心血管和冠心病死亡HR分别为1.48、1.49和1.59。
核心结论
- 痛风患者存在持续的全因和心血管死亡差距,即使校正血清尿酸和动脉粥样硬化性心血管危险因素后仍存在,支持痛风特异性通路(如发作期炎症)的作用。
- 这些发现提示当前诊疗存在差距,尤其在女性中,黑人患者中可能也存在。
研究设计与样本
- 使用美国全国性系列前瞻队列,评估现患痛风与全因及心血管死亡的独立关联,校正血清尿酸、动脉粥样硬化性心血管危险因素、合并症、用药和肾功能,并比较早期(1988-1994基线)和晚期(2007-2016基线)队列的死亡率。
- 在英国全国性队列(2006-2010基线)的痛风患者中重复晚期队列的发现。
主要发现
- 美国早期和晚期队列中现患痛风患者的全因死亡校正HR分别为1.20(1.03-1.40)和1.19(1.04-1.37);进一步校正血清尿酸后分别为1.19(1.02-1.38)和1.19(1.03-1.37)。
- 英国晚期队列痛风患者全因死亡校正HR为1.61(1.47-1.75);这些关联在女性中更大(P=0.04),在黑人个体中突出。
- 美国晚期队列心血管死亡校正HR为1.39(1.09-1.78);英国新发痛风患者循环系统、心血管和冠心病死亡的校正HR分别为1.48(1.24-1.76)、1.49(1.20-1.85)和1.59(1.26-1.99)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gout flares are followed by transient major cardiovascular (CV) risk, implicating the role of inflammation; the aim of this study was to determine whether premature mortality rates in patients with gout and CV risk are independent of serum urate (SU) and atherosclerotic CV disease (ASCVD) risk factors. METHODS: Using serial US nationwide prospective cohorts, we evaluated the independent association of prevalent gout with all-cause and CV mortality, adjusting for SU, ASCVD risk factors, comorbidities, medications, and kidney function and compared mortality rates between the early (1988-1994 baseline) and late cohorts (2007-2016 baseline). We replicated late cohort findings among patients with gout in a nationwide UK cohort (2006-2010 baseline). RESULTS: Adjusted hazard ratios (HRs) for mortality rates in patients with prevalent gout were similar in early and late US cohorts (1.20 [1.03-1.40] and 1.19 [1.04-1.37], respectively); HRs with further adjustment for SU were 1.19 (1.02-1.38) and 1.19 (1.03-1.37), respectively. Adjusted HR among patients with gout from the UK late cohort was 1.61 (1.47-1.75); these associations were larger among women (P = 0.04) and prominent among Black individuals. Adjusted HR for CV mortality rates in the late US cohort was 1.39 (1.09-1.78); those for circulatory, CV, and coronary heart disease deaths among UK patients with incident gout were 1.48 (1.24-1.76), 1.49 (1.20-1.85), and 1.59 (1.26-1.99), respectively. CONCLUSIONS: Patients with gout experience a persistent mortality gap in all-cause and CV deaths, even adjusting for SU and ASCVD risk factors, supporting a role for gout-specific pathways (eg, flare inflammation). These findings suggest gaps in current care, particularly in women and possibly among Black patients.
引用
- McCormick N, Lin K, Yokose C, et al. Unclosing Premature Mortality Gap Among Patients With Gout in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors. Arthritis Care Res (Hoboken). 2024. PMID: 38191784. doi:10.1002/acr.25292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。